Valeant Pharmaceuticals International has signed an agreement to acquire Dermik, a dermatology unit of Sanofi in the U.S. and Canada, for approximately $425 million. Dermik’s portfolio includes therapeutic and aesthetic dermatology brands such as Benzaclin for the treatment of acne, Carac for the treatment of keratoses, and Sculptra, a facial injectable for the correction of facial wrinkles and folds. The acquisition includes worldwide rights to Sculptra Aesthetic (injectable poly-L-lactic acid...